- Home
- CRVO vs CNTB Comparison
CRVO vs CNTB Comparison
Compare CRVO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- CNTB
- Stock Information
- Founded
- CRVO 2001
- CNTB 2012
- Country
- CRVO United States
- CNTB United States
- Employees
- CRVO N/A
- CNTB N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- CNTB Health Care
- Exchange
- CRVO Nasdaq
- CNTB Nasdaq
- Market Cap
- CRVO 67.4M
- CNTB 54.4M
- IPO Year
- CRVO N/A
- CNTB 2021
- Fundamental
- Price
- CRVO $6.96
- CNTB $1.53
- Analyst Decision
- CRVO Strong Buy
- CNTB Strong Buy
- Analyst Count
- CRVO 7
- CNTB 2
- Target Price
- CRVO $19.33
- CNTB $7.50
- AVG Volume (30 Days)
- CRVO 162.5K
- CNTB 156.2K
- Earning Date
- CRVO 08-08-2025
- CNTB 09-04-2025
- Dividend Yield
- CRVO N/A
- CNTB N/A
- EPS Growth
- CRVO N/A
- CNTB N/A
- EPS
- CRVO N/A
- CNTB N/A
- Revenue
- CRVO $9,308,215.00
- CNTB $26,033,000.00
- Revenue This Year
- CRVO N/A
- CNTB N/A
- Revenue Next Year
- CRVO N/A
- CNTB N/A
- P/E Ratio
- CRVO N/A
- CNTB N/A
- Revenue Growth
- CRVO 15.14
- CNTB N/A
- 52 Week Low
- CRVO $1.80
- CNTB $0.51
- 52 Week High
- CRVO $20.63
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- CRVO 51.63
- CNTB 66.20
- Support Level
- CRVO $5.45
- CNTB $1.05
- Resistance Level
- CRVO $7.55
- CNTB $1.20
- Average True Range (ATR)
- CRVO 0.59
- CNTB 0.09
- MACD
- CRVO 0.14
- CNTB 0.01
- Stochastic Oscillator
- CRVO 75.71
- CNTB 82.76
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.